Myriad Identifies Cancer Target Using In-house System | GenomeWeb

NEW YORK, Oct. 9 – Myriad Genetics of Salt Lake City said Tuesday it had discovered a drug target for treating cancer using its proteomics technology.

In a statement, Myriad said that the ProNet technology allowed the company to look at protein interactions involved in apoptosis and to apply the knowledge garnered to identifying a target for cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."